Overview

Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP)

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
0
Participant gender:
All
Summary
The aim of the present study was to evaluate the use of drotaverine hydrochloride versus hyoscine-N-butylbromide in reducing duodenal motility during diagnostic and therapeutic ERCP.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Changhai Hospital
Treatments:
Butylscopolammonium Bromide
Drotaverin
Papaverine
Scopolamine
Scopolamine Hydrobromide
Criteria
Inclusion Criteria:

- All patients undergoing ERCP above the age of 18 years

Exclusion Criteria:

- Patient with Billroth II gastrectomy

- Known previous sphincterotomy

- Active acute pancreatitis before ERCP

- Ongoing acute cholangitis before ERCP

- Hypotension (systolic blood pressure < 100 mmHg)

- Second-degree and third-degree atrioventricular block

- Heart failure

- Glaucoma

- Obstructive uropathy

- Impaired renal function (serum creatinine > 133μmol/L)

- Pregnant or breastfeeding women